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I N T R O D U C T I O N
In the past few years there have been renewed calls to phase
out or even ban antibiotics given to animals as growth promo-
ters. For example, these were made at aWHO conference in
Berlin in 1997, at a European meeting in Copenhagen in Sep-
tember 1998, and in recent reports from the House of Lords
and from Directorate General XXIV of the European Com-
mission. However, an interdisciplinary conference was held at
Georgetown University in spring 1999 and included physi-
cians, congressional sta¡, and regulatory agencies, including
the Food and Drug Administration and Centers for Disease
Control and Prevention (CDC). It was agreed that a rigorous
risk assessment should be undertaken before conclusions were
reached on the future of feed additives in livestock production,
and, indeed, it has recently been announced by the FDA that a
quantitative risk assessment will be carried out of the impact
of growth promoters on enterococcal resistance.
Used as growth promoters from the 1950s, various antibio-
tics were found to increase growth in young animals by up to
8% [1]. The possible actions in the gut include altering the
£ora, increasing nutrient absorption, and diminishing toxin
production. Initially, a wide range of antibiotics was used, but
because resistant organisms emerged, various countries intro-
duced restrictions. Thus, in 1969, the Swann Report recom-
mended that therapeutic antibiotics should not be used as
growth promoters. Later, the European Union (EU) banned
certain antibiotics as growth promoters, but the USA did not
introduce similar restrictions. In April 1997, avoparcin was
banned in the EU, as were virginiamycin, bacitracin, spiramy-
cin, and tylosin in July 1999.The EU directive (70/524) stipu-
lates that not only must additives favorably a¡ect livestock
production, but that they should not endanger human
health.
Clearly, any decision to ban or phase out should be based
on scienti¢c studies. The EU avoparcin ban was implemented
despite scienti¢c advice from the EU's own Scienti¢c Com-
mittee on Animal Nutrition (SCAN) that there were insu¤-
cient data to support it. Moreover, SCAN reviewed the
evidence for the unilateral Danish ban on virginiamycin in
1998, also concluding that this was insu¤cient.
A major problem is the non-rigorous literature: so many
of the data are recent and not peer-reviewed that drawing ¢rm
conclusions is di¤cult. In particular, there are few well-
planned and conducted studies, as pointed out by Phillips [2].
Nevertheless, we review here publications and recent commu-
nications for two key antibioticsöavoparcin and virginiamy-
cinöbut not for the others, given the paucity of the data.
A V O P A R C I N
Avoparcin is a glycopeptide structurally related to vancomycin
and teicoplanin, and was widely used in Europe as a growth
promoter from the early 1970s until banned. Vancomycin-
resistant enterococci (VRE) in Europe were ¢rst reported in
the mid-1980s [3,4], and are now an important cause of hospi-
tal-acquired infection, almost exclusively in the USA [5].
Their acquired resistance mechanisms to glycopeptides are
complex, and three phenotypes (vanA, vanB and vanD) can be
distinguished [6].
The vanA resistance phenotype consists of high-level van-
comycin and teicoplanin resistance.The genes are often found
on a transposon that invitro is easily transferred to other enter-
ococci [6]. In the laboratory, the vanA gene cluster has also
been successfully transferred from Enterococcus faecalis to Sta-
phylococcus aureus [7].The vanB resistance phenotype consists of
variable levels of vancomycin resistance and susceptibility to
teicoplanin. The genes encoding the vanB resistance pheno-
type are more commonly chromosomal but can also be trans-
ferred. VanD is very rare. The van gene clusters confer
resistance to glycopeptides through similar mechanisms.
In the USA, avoparcin was never used in animals, whereas
in Europe it was widely used until banned [8]. In the USA,
only vancomycin is used for human disease, whereas in Eur-
ope, both vancomycin and teicoplanin are used. So, despite
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the very low incidence of VRE infections in Europe [9], was
there enough evidence to justify the ban?
To answer this, it is useful to compare the di¡erences in the
occurrence and spread of VRE in both continents, in humans
and animals [10].The prevalence of VRE in isolates inUS hos-
pitals, both inside and outside intensive care units, has been
rapidly increasing [5]. About 70% of isolates exhibit the vanA
phenotype and about 25% the vanB phenotype [11,12].
Strategies to eradicateVRE fromUS hospitals have gener-
ally failed. Moreover, mostVRE have high-level resistance to
ampicillin and the aminoglycosides, leaving few options for
treatment [12]. As opposed to hospitalized patients,VRE have
not been found in community-based volunteers in the USA
[13,14]. Likewise, VRE have not been found in American
food-producing animals and pet animals [13,15,16].These stu-
dies suggest that VRE are not present in the gut of humans
and animals in theUSA. However, only two studies have been
performed in humans [13,14] and three studies in animals
[13,15,16]; the microbiological methods were inadequate and
only a few samples were studied. Clearly, better-designed stu-
dies should be performed in the USA to con¢rm the absence
of VRE in the community and animals. In particular, a broth
enrichment step in the culture of feces almost doubles the rate
of detection of VRE carriage [17].
In Europe, VRE have spread only in high-risk units such
as intensive care, transplant, hematology and renal units. The
outbreaks were mostly caused by clonal dissemination of sin-
gle strains of vanA-containing E. faecium, although several
strains have been involved in hospital units in theUK. In con-
trast to the USA, the outbreaks have been successfully con-
tained in Europe through infection control and/or reduction
of antibiotic selective pressure.Thus,VRE infection is not per-
sistent in European hospitals. On the other hand,VRE can be
isolated from the feces of as many as 12% of healthy volunteers
[18].
Several studies have shown that VRE can be found in farm
and pet animals in Europe [18,19]. These VRE have always
been of the vanA phenotype. In contrast to the VRE isolated
in US hospitals, those from humans and animals in Europe,
e.g. in Belgium [20], remain generally susceptible to ampicil-
lin and to the aminoglycosides. In addition, the susceptibility
pro¢les of the vanAphenotype of E. faecium from food animals
are comparable with those from community fecal samples. On
the other hand, where the vanB phenotype occurs in human
feces [21], this cannot be derived from animals, as it is not
found in the latter. In Australia it appears that vanB is the pre-
dominant phenotype found in humanVRE cases, which con-
trasts with the situation in Europe, despite the fact that
avoparcin has been widely used on both continents [22]. In
European hospitals with a VRE problem, multiply resistant
strains are reported that are similar to those in the USA, rather
than those in European animals, with resistance to ampicillin,
to high-level gentamicin, and to virtually all antimicrobials
[23,24].
VRE may spread clonally from one host to another, or
there may be horizontal transfer of vancomycin resistance
genes between E. faecium of human and animal origins, and/or
from a common reservoir of glycopeptide resistance.Thus the
vanA resistance genes may have been introduced into the com-
munity via the food chain [25]. Although the experimental
ingestion by a single subject of 10 7 CFU of chicken-derived
VRE resulted in the excretion of VRE for about 3 weeks [26],
the interpretation of these ¢ndings has been questioned with
regard to the microbiological detection and identi¢cation
methodology, and the lack of con¢rmation that the ingested
and excreted strains were identical [27]. In addition, it has
proved remarkably di¤cult to ¢nd indistinguishable clone
pairs of vanA phenotypes of E. faecium in fecal samples from
humans and animals, although this has been shown for a tur-
key farmer and his £ock [28], and in two instances for epide-
miologically unrelated pig and human fecal isolates by
Descheemaeker et al [20]. Any generalized deduction from
these observations about the unidirectional spread of VRE
from animals to humans would be highly speculative. Such
observations may simply indicate the wide distribution of
VRE clones or the existence of a common reservoir [20].
An alternative suggestion is that the glycopeptide-resistant
genetic elements spread horizontally and contribute to vanco-
mycin resistance in humans [29,30].The transposon originally
identi¢ed as conferring resistance, Tn1546, displays striking
diversity due to point mutations, insertion of IS elements, and
deletions in the intergenic regions. These variations provide
potential markers to type and trace the spread of transposon-
mediated glycopeptide resistance [30,31]. However, the stabi-
lity of the elements must be established before they can be used
as epidemiologic markers and the true signi¢cance of their
heterogeneity can be resolved [30]. Some have found that ele-
ments of vanA are shared between organisms of human and
animal origins [20,29^31] and others have not [32]. For exam-
ple, in a collection of 132 vancomycin-resistant E. faecium
strains from Belgium, eight transposon RFLP types were
found [20].The two predominant types, one indistinguishable
fromTn1546 (`type1') and amore common close variant (`type
2'), were found inVRE from both animal and human feces. A
statistically signi¢cant association was found between this
type 2 and pigVRE isolates. These ¢ndings are in agreement
with results reported by Jensen et al [29],Woodford et al [30],
and Willems et al [31]. Thus, VRE isolates from human and
farm animals may share a common vancomycin resistance
gene pool. These results would suggest that genetic diversity
in Tn1546 can be successfully exploited for tracing the routes
of transmission of vancomycin resistance genes. Further stu-
dies are therefore needed, and, for example,VRE from di¡er-
ent origins should be exchanged among research groups in
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several countries to compare glycopeptide-resistant clones
and transposon types.
In The Netherlands, the use of avoparcin in turkey £ocks
has been correlated with a high frequency of VRE compared
with £ocks not fed avoparcin, although details are scant [28].
More evidence of the role of avoparcin in the emergence of
VRE in food animals was provided recently. Bager et al [33]
showed a statistically signi¢cant decline of VRE isolated from
broilers after the ban of avoparcin in 1995 in Denmark. Kruse
et al [34] also demonstrated a strong and statistically signi¢-
cant association between the use of avoparcin in Norwegian
poultry production and the occurrence of VRE. Pantosti et al
[35] demonstrated, 18months after the banning of avoparcin,
a decline in the percentage of poultry meat samples containing
vanA gene-positiveVRE from 14.6% to 8%.Thus, avoparcin
consumption data correlate well with the prevalence of vanA
VRE in animals. SeveralUS studies have correlated the acqui-
sition of VRE by humans with the intensity and duration of
antimicrobial therapy. Clonal dissemination has been asso-
ciated with oral as well as intravenous vancomycin [36]. Con-
sumption data in the USA compared with those of major
European countries from1984 to 1996 show an acceleration of
vancomycin use in the early 1980s, and further acceleration
when oral formulations became available in the mid-1980s.
During 1996, for example, 11 200 kg of vancomycin was used
in the USA, compared with 60 kg for the whole of The Neth-
erlands [8,37]. Its intravenous use may have increased because
of the emergence of multiresistant coagulase-negative or -
positive staphylococci, enterococci, and Streptococcus pneumo-
niae. The increase in oral use in the USA is possibly a result of
its widespread prescription for antibiotic-associated colitis.
The vancomycin consumption data correlate well with the
greater prevalence of VRE in US hospitals compared with
Europe. Moreover, its spread in the former in the 1990s may
have been preceded by increased resistance of E. faecium to
ampicillin and aminoglycosides. Indeed, high-level resistance
to ampicillin and gentamicin among E. faecium isolated in one
institution signi¢cantly increased over the 22 years from 1968
[38]. Given the mobility of the vanA and vanB resistance genes,
transfer of these genes to ampicillin- and gentamicin-resistant
E. faeciummay have occurred subsequently.Multiresistant van-
comycin-resistant E. faecium strains may have been further
selected by the use of b-lactam antibiotics and aminoglyco-
sides. E. faecium is less susceptible to b-lactam antibiotics than
E. faecalis because of low a¤nity or the overproduction of
penicillin-binding proteins [39].This might partly explain the
greater spread of E. faecium compared to other enterococci.The
vanAgene has been linkedwith gentamicin resistance [40] and
the vanB gene with ampicillin resistance in enterococci [41].
Thus, the emergence of ampicillin and aminoglycoside resis-
tance may be a prerequisite for the emergence and nosocomial
spread of VRE.
V IR G I N IA M Y C IN
Used extensively as a growth promoter for 30 years, virginia-
mycin consists of a synergistic mixture of type A and type B
streptogramins. In humans, oral pristinamycin, also a mixture
of streptogramin A and B, has been used for 30 years for sta-
phylococcal infections, particularly in France, where topical
virginiamycin was also used. Recently, dalfopristin/quinu-
pristin (Synercid), a mixture of type A and B semisynthetic
streptogramins, has been developed for human intravenous
use [42]. Synercid has promising activity against methicillin-
resistant Staphylococcus aureus (MRSA), and against VRE,
excluding E. faecalis [43].
The recent controversy has arisen because animal-derived
virginiamycin-resistant organisms (or their genetic determi-
nants) are cross-resistant with Synercid and might cause
human infections. There is anecdotal evidence of clinical
infectionwith streptogramin-resistant enterococci in humans,
but the emergence of resistance was associated with therapeu-
tic use of Synercid.
Resistance to streptogramin A, but not streptogramin B,
confers resistance to the combination. The mechanism of
streptogramin resistance in one strain of human E. faecium is
inactivation of the streptogramin A component by an acetyl-
transferase encoded by the satA gene [44] and the satG gene
[45]. In human staphylococcal isolates, type A streptogramins
are resisted by acetyltransferase enzymes (encoded by vat, vatB,
vatC) or active e¥ux (encoded by vga, vgaB). All these
mechanisms are reported to be plasmid-mediated. Little is
known about the genetic mechanisms in animal isolates.
After 30 years' use of virginiamycin in animals, streptogra-
min-resistant staphylococcal or streptogramin-resistant enter-
ococcal infections in humans are still rare, as con¢rmed by
Jones et al [46]. Of 28 029 clinical isolates of Gram-positive
cocci from 200 centers in the USA and Canada, 99.8% of 1011
E. faecium isolates were sensitive to Synercid, as were 99.8% of
519 VRE isolates. More than 99% of the 10 216 isolates of Sta-
phylococcus aureus were sensitive to Synercid. Even in France,
with the additional selective pressure of pristinamycin, there is
no evidence of increasing streptogramin resistance. Of 895
isolates of MRSA from 95 non-university hospitals, 98.5%
were sensitive to both pristinamycin and Synercid.
In 1997, van den Bogaard found pristinamycin-resistant
enterococci in the feces of Dutch pigs [47]. However, these
were not speciated, which is important, as E. faecalis is intrinsi-
cally resistant to streptogramins.The Danish monitoring pro-
gram also reported virginiamycin resistance in about half of
the isolates of E. faecium from pigs and broilers [48,49].
Although a control group was not included, Welton et al
showed the emergence of streptogramin-resistant E. faecium
from cloacal cultures of turkeys fed virginiamycin [16].
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From The Netherlands, a letter reported enterococci
(again, non-speciated) resistant to pristinamycin in 30% of
healthy suburban residents [47]. Nevertheless, confusingly, the
1997 Danish Danmap Report found [50] only 2% of healthy
humans with stool samples containing streptogramin-resis-
tant E. faecium. Hence, rigorous studies are needed to deter-
mine the prevalence of streptogramin-resistant enterococci
and to determine whether these organisms re£ect transitory
excretion or colonization or represent a threat to human
health.
D IS C U S S IO N
Understandable anxieties about antibiotic resistance, with its
overtones of human health impairment, can engender evan-
gelical calls for premature action. Nevertheless, the impor-
tance of therapeutic use in humans to the development of such
resistance should not be underestimated. Our review of the
data provides no rigorous evidence that the two growth pro-
moters avoparcin and virginiamycin used in animals create
antibiotic-resistant bacterial strains in humans that cause clini-
cal infections, and there are insu¤cient data for the other anti-
biotics used in this way. However, for avoparcin there are
recent studies suggesting that vanA-positive VRE in feces of
healthy humans may be derived from animals. Fortunately,
these VRE have not been associated with an emergence of
VRE infections in humans in Europe. Direct evidence for
such a link will be di¤cult to demonstrate, given the molecu-
lar complexity of the problem. Such a sequence might com-
prise: presence of vanA genes in enterococci in animals;
selection of theseVRE in animals following the use of avopar-
cin or other antibiotics and horizontal gene transfer; ingestion
of food contaminated with vanA-positive VRE by humans;
selection of theseVRE in humans following the use of glyco-
peptides or other antibiotics and horizontal gene transfer;
clinical infectionwith vanA-positiveVRE in humans.
Our understanding is supported by a recent comprehensive
review of the literature by the Heidelberg Appeal Nederland
(HAN) Foundationöan independent alliance of almost 200
senior academicsöwhich also concluded [51] that d`ocumen-
ted in-vivo cases showing spread of antimicrobial resistant
Gram-positive bacteria from livestock to humans are in
essence non-existent'.
C O N C L U S IO N S
We need to clarify the issue of gene transfer and bacterial
population dynamics. Speci¢cally, the following questions
need to be answered: To what extent do growth promoters
select for resistant organisms in animals? What is the preva-
lence of resistant enterococci in human populations? If they
are in the gut transitorily, can they transfer resistance to other
organisms? If so, towhat extent? Do animal enterococci colo-
nize humans? If so, do they cause disease? Answers to these
questions need well-designed studies and would take years of
research, but would enable a proper risk analysis. Banning
antibiotics as growth promoters in animals will not solve the
problemof antibiotic resistance in hospitals.
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